The Side Effects and Correlates of OROS-Methylphenidate in the Treatment of Children and Adolescents with ADHD.
- Author:
Jin Sun KIM
1
;
Bung Nyun KIM
;
Soo Churl CHO
;
Min Sup SHIN
;
Hee Jeong YOO
;
Jae Won KIM
;
Dong Ho SONG
;
Dong Won SHIN
;
Yoo Sook JOUNG
;
Keun Ah CHEON
;
Yee Jin SHIN
;
Ye Ni KIM
;
Eun Hye HA
Author Information
1. Department of Psychiatry, Seoul National University Hospital, Seoul, Korea. kbn1@snu.ac.kr
- Publication Type:Original Article
- Keywords:
ADHD;
OROS-MPH;
Side Effects;
Drug Response
- MeSH:
Adolescent;
Anorexia;
Appetite;
Blood Pressure;
Body Weight;
Child;
Electrocardiography;
Follow-Up Studies;
Heart Rate;
Humans;
Sleep Initiation and Maintenance Disorders
- From:Journal of the Korean Academy of Child and Adolescent Psychiatry
2010;21(2):63-71
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The aim of this study was to investigate the effect of the clinical and demographic variables such as body weight, dosage, family history of attention-deficit hyperactivity disorder (ADHD), and psychiatric co-morbidity on the side-effects of OROS-Methylphenidate (OROS-MPH), and to evaluate the relationship between drug response and side effect severity. METHODS: A total of 144 children (ages 6-18) with diagnosed ADHD were treated with OROS-MPH. Children were examined at baseline and after 1, 3, 6, 9, and 12 weeks of each treatment condition. The stimulant drug side effect rating scale (SERS), pulse rate, systolic blood pressure, diastolic blood pressure, and electrocardiogram (ECG) were evaluated to assess side effect profiles. Changes in these parameters from baseline were examined and analyzed. RESULTS: Anorexia (30.95%) and insomnia (13.10%) were the most commonly reported side effects during this study. Insomnia and loss of appetite score increased at one week follow-up, but was sustained or decreased as treatment progressed. Small but significant increases in pulse rate and diastolic blood pressure were observed during treatment; however, no clinically meaningful changes in ECG parameters were noted during the study. Low body weight, high dosage of OROS-MPH, and family history of ADHD were associated with cardiovascular side effect. In contrast, there was no significant relationship between OROS-MPH treatment response and the severity of side effect and no difference resulted between the responder and non-responder groups with respect to OROS-MPH dosage in the 12 weeks of follow-up. CONCLUSION: To the best of our knowledge, this study is the first Korean study to investigate comprehensive side effect profiles and their correlates in OROS-MPH treatment for ADHD children. OROS-MPH was well tolerated with no clinically significant side effects during the treatment period. In conclusion, low body weight, high dosage of OROS-MPH, and family history of ADHD could be used as predictive factors in increasing pulse rate and blood pressure.
